Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q2 2018 · 10-Q
Revenue$411.00K$411.00K−8.1% vs Q2 2017 Net Income-$2.03M-$2.03MN/M vs Q2 2017 EPS Diluted-$0.03-$0.03N/M vs Q2 2017 Operating Income-$2,028,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$1,099,000N/M Margins · derivedOperating margin-493.4%−179.3 pt vs Q2 2017
Net margin-493.2%−283.8 pt vs Q2 2017
ended Jan 31, 2018 · filed Mar 14, 2018 · 42 d after period end